Ovarian function after allogeneic hematopoietic stem cell transplantation in children and young adults given 8-Gy total body irradiation-based reduced-toxicity myeloablative conditioning

Pediatr Transplant. 2019 May;23(3):e13372. doi: 10.1111/petr.13372. Epub 2019 Feb 3.

Abstract

Background: The spectrum of late sequelae after hematopoietic stem cell transplantation (HSCT) includes infertility, which is the most frequent complication. Some reports suggested that ovarian function may be better preserved in females undergoing HSCT with reduced-intensity conditioning (RIC) than with conventional myeloablative conditioning (MAC). However, the impact of HSCT after 8-Gy TBI-based reduced-toxicity MAC (RTMAC), whose efficacy is between those of conventional MAC and RIC, on ovarian function remains unclear.

Procedure: A single-center retrospective analysis of data derived from patient information for all the children who underwent transplantation at the Shinshu University Hospital was carried out. Patients who underwent 8-Gy total body irradiation (TBI)-based RTMAC before HSCT were analyzed.

Results: A total of 36% (five of 14) of the patients developed primary ovarian insufficiency (POI) during the observation period, but serum follicle-stimulating hormone levels reduced to normal range with spontaneous menstruation in two, implying the reversal of POI. Furthermore, only one (10%) of the 10 prepubertal patients (71%; 10/14) at the time of HSCT suffered from POI at the last observation, but all three post-pubertal patients developed POI (100%), and two (67%) continued to suffer from POI at the last observation.

Conclusions: Taken together, 8-Gy TBI-based RTMAC before HSCT may decrease the possibility of POI compared with conventional MAC, especially in prepubertal patients. A longer follow-up will be required to ascertain whether a normal pregnancy and delivery can occur in such patients.

Keywords: 8-Gy TBI; HSCT; POI; children; hematological malignancies.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Follicle Stimulating Hormone / blood
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Infant
  • Infertility, Female / etiology*
  • Leukemia / complications
  • Leukemia / therapy*
  • Myeloablative Agonists / therapeutic use*
  • Ovary / radiation effects*
  • Primary Ovarian Insufficiency / prevention & control*
  • Research Design
  • Retrospective Studies
  • Transplantation Conditioning*
  • Whole-Body Irradiation / adverse effects
  • Young Adult

Substances

  • Myeloablative Agonists
  • Follicle Stimulating Hormone